Advertisement
Canada markets open in 1 hour 56 minutes
  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CAD/USD

    0.7294
    -0.0003 (-0.04%)
     
  • CRUDE OIL

    81.70
    +0.13 (+0.16%)
     
  • Bitcoin CAD

    91,025.37
    +1,371.81 (+1.53%)
     
  • CMC Crypto 200

    1,380.03
    -2.63 (-0.19%)
     
  • GOLD FUTURES

    2,352.20
    +5.30 (+0.23%)
     
  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     
  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     
  • NASDAQ futures

    20,038.75
    +119.50 (+0.60%)
     
  • VOLATILITY

    12.59
    +0.11 (+0.88%)
     
  • FTSE

    8,236.97
    +31.86 (+0.39%)
     
  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     
  • CAD/EUR

    0.6796
    +0.0009 (+0.13%)
     

MindMed to Participate in June Conferences

NEW YORK, May 28, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences:

  • BIO International Convention 2024

    • Panel Name: Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation

    • Date and Time: Tuesday, June 4, 2024 at 4:15 pm PDT

    • Location: San Diego, CA

  • Jefferies 2024 Global Healthcare Conference

    • Format: 1x1 investor meetings only

    • Dates: June 5-6, 2024

    • Location: New York, NY

ADVERTISEMENT

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528659571/en/

Contacts

For Media: media@mindmed.co
For Investors: ir@mindmed.co